non fda approved semaglutide Approval vs Compounded Alternatives The FDA announced plans to

The data seems to indicate that the earlier the intervention with a scar, the better clinical result were going to get, says Mathew Avram, MD, a board-certified dermatologist in Boston

Looking for More

Patients must be at least 18 years old and meet one of the following clinical requirements when GLP-1 therapy begins: A body mass index, or BMI, of 35 or higher A BMI between 30 and 34.99 with at least one qualifying health condition A BMI between 27 and 29.99 with at least one qualifying higher-risk health condition For someone with a BMI between 30 and 34.99, qualifying conditions may include heart failure with preserved ejection fraction, uncontrolled high blood pressure, stage 3a or higher chronic kidney disease, prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease

PMID: 23466488

The obesity segment is expected to witness substantial growth rate of CAGR 55.21% during the forecast period as the global burden of obesity continues to escalate, driving demand for effective pharmacological interventions

Research (mostly in animal models, its important to state) has shown it can help heal ulcers, repair intestinal damage from NSAIDs, and manage conditions like inflammatory bowel disease (IBD)